ALK1 as an emerging target for antiangiogenic therapy of cancer
about
Signal transduction inhibitors in treatment of myelodysplastic syndromesSpecificity and Structure of a High Affinity Activin Receptor-like Kinase 1 (ALK1) Signaling ComplexBMP9 is a proliferative and survival factor for human hepatocellular carcinoma cellsLRG1 promotes angiogenesis by modulating endothelial TGF-β signalling.Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritisA phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumorsPhase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway.Metformin inhibits ALK1-mediated angiogenesis via activation of AMPK.GDF5 regulates TGFß-dependent angiogenesis in breast carcinoma MCF-7 cells: in vitro and in vivo control by anti-TGFß peptides.Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14Biomarkers in tumor angiogenesis and anti-angiogenic therapy.A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.Decreasing matrix modulus of PEG hydrogels induces a vascular phenotype in human cord blood stem cellsBMP9 and BMP10 are critical for postnatal retinal vascular remodeling.Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229NIncreased caveolin-1 in intervertebral disc degeneration facilitates repairDeficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic disseminationBMP9 signaling in stem cell differentiation and osteogenesis.Inhibition of apelin expression switches endothelial cells from proliferative to mature state in pathological retinal angiogenesis.Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development.Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formationSystemic neutralization of TGF-β attenuates osteoarthritisHalofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone.Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression.Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6.Novel targets for VEGF-independent anti-angiogenic drugs.The expression of activin receptor-like kinase 1 among patients with head and neck cancer.Bi-directional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde?Therapies currently in Phase II trials for malignant pleural mesothelioma.Understanding and targeting resistance to anti-angiogenic therapies.Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy.Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.Therapy of advanced squamous cell carcinoma of the skin.Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.Diversity is in my veins: role of bone morphogenetic protein signaling during venous morphogenesis in zebrafish illustrates the heterogeneity within endothelial cellsTGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets.Detecting and targetting oncogenic fusion proteins in the genomic era.
P2860
Q26829903-E3C107DD-7C1D-44BA-8752-664D9664B922Q27681271-94021EA0-88B1-4ECF-AE3F-442C67DCDC85Q28296361-D4896DC6-F0A8-4645-89B1-EB359D207257Q28508560-808E9DCC-9B79-46FF-A984-BE9299354850Q30540454-B22C1D6B-E845-4FA7-8ADE-0AB4B48E0EE3Q33431483-2FC497C0-7B5F-4E3F-884A-232F262076A7Q33433311-B5B06725-7C5A-4D11-8925-08154A2F753AQ33719706-D264E60D-3049-4CCE-A327-BB9575660431Q33779258-C778B337-05D6-45DC-920E-D254447D626EQ34505275-E7D4B3D3-537A-4C42-8BB8-D949A44019A6Q34540047-2E004ED4-5D3F-4ECA-B481-BF2E526BA0EFQ35170438-967DD21F-E141-4BB3-BD14-C154D6FA93ABQ35536088-33B22889-9286-42ED-90A7-82D10532FBAFQ35547649-AB413AF2-A037-4860-9DB2-5B466DD3F869Q35752197-1ED79099-631C-4E6F-9576-CACE410B9244Q36057921-34019399-5B99-41A7-8961-7EB6D6881B70Q36191443-DC3E5FF1-253C-4C24-A9DA-7C055EFFDE2AQ36651774-C536E13D-10FF-4E4C-8CBE-1F8D7F49ADDDQ36694132-1E3F07A5-48BE-4A61-9C95-9A6EC27E70ACQ36796379-663101FF-A537-4225-90DB-8785B8E2F0C1Q36927604-CA75F830-BD57-4B1A-A9ED-0D36F9509F3DQ37031726-4AE356D8-4D65-4140-AC89-1B1DE7BAF852Q37047011-A617F76F-E883-40B0-B484-6E2107EEB00AQ37146817-440C8137-2FE1-493D-BAB2-77E86FBBDBBDQ37235742-1C705E25-1B72-4834-9934-76A5E9D8B816Q37340780-23439839-6DB9-43B4-972C-0A8BA3849F9DQ37611674-3F9503A4-EC7E-4EE0-9CC0-E282FF7CF773Q37683823-97051A97-7C55-411E-8D0A-500F060330FCQ37984612-ECD8DCCE-FA6A-45CC-853B-7BAEF05C972CQ38085283-846C9E62-BDE0-43BB-B44F-2BFAF51F9215Q38115632-333A7A0C-1E81-40EF-A61C-1D604BA59A01Q38118385-7F76E52A-166F-474F-95D8-94C1C556292EQ38133568-57F0A4C9-37FD-48EE-9F63-F36B2ECAA3FAQ38140116-BA59FE6B-6B27-4821-AA59-1E80FF627FCEQ38174516-ACC79747-BF90-47ED-9192-8DAD77A1732BQ38197119-9CEFDB01-8413-4FF4-8620-A7C94265930FQ38221292-3F303AB4-985D-4492-AFAA-496A19E9C36BQ38233800-7CBC287B-839E-4582-AE8D-DF5971913C29Q38256407-F5C57119-A362-448B-BE2A-D81D39531F4EQ38336067-36A4EBEA-639F-4BF0-A99E-5138A96D02D8
P2860
ALK1 as an emerging target for antiangiogenic therapy of cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
ALK1 as an emerging target for antiangiogenic therapy of cancer
@ast
ALK1 as an emerging target for antiangiogenic therapy of cancer
@en
type
label
ALK1 as an emerging target for antiangiogenic therapy of cancer
@ast
ALK1 as an emerging target for antiangiogenic therapy of cancer
@en
prefLabel
ALK1 as an emerging target for antiangiogenic therapy of cancer
@ast
ALK1 as an emerging target for antiangiogenic therapy of cancer
@en
P2860
P1433
P1476
ALK1 as an emerging target for antiangiogenic therapy of cancer
@en
P2093
Kristian Pietras
Sara I Cunha
P2860
P304
P356
10.1182/BLOOD-2011-01-330142
P407
P577
2011-04-05T00:00:00Z